Kura Oncology, Inc. (KURA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 3.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 20.52% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
- Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
- Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
- Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes
- Kura spins diabetes work into a Lilly-backed biotech startup
- Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Kura Oncology, Inc..
Full KURA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.